GlassScriptPhysician profile
Kenneth H Crager
NPI 1902891120
$5,081.71
in general payments reported to CMS, 2019-2025
25 companies · $710 in 2025
The $710 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,675 · 2020: $314 · 2021: $216 · 2022: $501 · 2023: $946 · 2024: $719 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.76 |
| Education | $106.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,824.85 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $859.78 | 2019-2024 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $587.99 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $339.45 | 2021-2024 | Saphnelo |
| Janssen Biotech, INC. | $248.89 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.10 | 2019-2024 | |
| Genzyme Corporation | $185.09 | 2019-2025 | |
| Lilly USA, LLC | $135.61 | 2023 | Taltz |
| Celgene Corporation | $121.92 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $92.58 | 2019 | |
| Ucb, INC. | $77.39 | 2022-2024 | Cimzia, Bimzelx |
| Fresenius Kabi USA, LLC | $65.71 | 2023-2024 | Idacio |
| Aurinia Pharma U.S., INC. | $52.01 | 2024-2025 | Lupkynis |
| Horizon Therapeutics Plc | $49.41 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $31.87 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.94 | 2019 | |
| Esperion Therapeutics, INC. | $22.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.66 | 2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $19.53 | 2024 | Acthar |
| Vanda Pharmaceuticals INC. | $18.47 | 2019 | |
| Sandoz INC. | $15.71 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $15.19 | 2019 | |
| Merck Sharp & Dohme LLC | $12.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2019 | |
| Organon LLC | $7.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Crager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.